{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,5]],"date-time":"2026-02-05T05:22:46Z","timestamp":1770268966404,"version":"3.49.0"},"reference-count":17,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":1492,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2011,8]]},"DOI":"10.1111\/j.1756-185x.2011.01643.x","type":"journal-article","created":{"date-parts":[[2011,8,5]],"date-time":"2011-08-05T09:11:11Z","timestamp":1312535471000},"page":"261-266","source":"Crossref","is-referenced-by-count":16,"title":["Decrease of CD68 and MMP-3 expression in synovium by treatment of adalimumab for rheumatoid arthritis"],"prefix":"10.1111","volume":"14","author":[{"given":"Katsuaki","family":"KANBE","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Junji","family":"CHIBA","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Atsushi","family":"NAKAMURA","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2011,8,5]]},"reference":[{"key":"10.1111\/j.1756-185X.2011.01643.x-BIB1|cit1","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1056\/NEJM200011303432202","article-title":"Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-tumor necrosis factor trial in rheumatoid arthritis with concomitant therapy study","volume":"343","author":"Lipsky","year":"2000","journal-title":"N Engl J Med"},{"key":"10.1111\/j.1756-185X.2011.01643.x-BIB2|cit2","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1136\/ard.2005.044404","article-title":"Long term efficacy and safety of adalimumab plus methotrexate in patients with rheumatoid arthritis: ARMADA 4\u2003year extended study","volume":"65","author":"Weinblatt","year":"2006","journal-title":"Ann Rheum Dis"},{"key":"10.1111\/j.1756-185X.2011.01643.x-BIB3|cit3","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1038\/ncprheum0339","article-title":"Switching tumor necrosis factor inhibitors: an opinion","volume":"2","author":"Keystone","year":"2006","journal-title":"Nat Clin Pract Rheumatol"},{"key":"10.1111\/j.1756-185X.2011.01643.x-BIB4|cit4","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1002\/art.21519","article-title":"The PREMIER study: a multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment","volume":"54","author":"Breedveld","year":"2006","journal-title":"Arthritis Rheum"},{"key":"10.1111\/j.1756-185X.2011.01643.x-BIB5|cit5","doi-asserted-by":"crossref","DOI":"10.1186\/ar2678","article-title":"Gene expression profiling in the synovium identifies a predictive signature of absence of response to adalimumab therapy in rheumatoid arthritis","volume":"11","author":"Badot","year":"2009","journal-title":"Arthritis Res Ther"},{"key":"10.1111\/j.1756-185X.2011.01643.x-BIB6|cit6","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1002\/art.1780390702","article-title":"Decrease in cellularity and expression of adhesion molecules by anti-tumor necrosis factor alpha monoclonal antibody treatment in patients with rheumatoid arthritis","volume":"39","author":"Tak","year":"1996","journal-title":"Arthritis Rheum"},{"key":"10.1111\/j.1756-185X.2011.01643.x-BIB7|cit7","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1001\/jama.1949.02900430001001","article-title":"Therapeutic criteria in rheumatoid arthritis","volume":"140","author":"Steinbrocker","year":"1949","journal-title":"JAMA"},{"key":"10.1111\/j.1756-185X.2011.01643.x-BIB8|cit8","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1002\/art.1780310302","article-title":"The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis","volume":"31","author":"Arnett","year":"1988","journal-title":"Arthritis Rheum"},{"key":"10.1111\/j.1756-185X.2011.01643.x-BIB9|cit9","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1136\/ard.49.11.916","article-title":"Judging disease activity in clinical practice in rheumatoid arthritis: first step in the development of a disease activity score","volume":"49","author":"Van der Heijde","year":"1990","journal-title":"Ann Rheum Dis"},{"key":"10.1111\/j.1756-185X.2011.01643.x-BIB10|cit10","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1136\/ard.52.12.870","article-title":"Cytokine expression in synovial membranes of patients with rheumatoid arthritis and osteoarthritis","volume":"52","author":"Farahat","year":"1993","journal-title":"Ann Rheum Dis"},{"key":"10.1111\/j.1756-185X.2011.01643.x-BIB11|cit11","first-page":"660","article-title":"Reduction of chemokine levels and leukocyte traffic to joints by tumor necrosis factor alpha blockade in patients with rheumatoid arthritis","volume":"60","author":"Taylor","year":"2000","journal-title":"Arthritis Rheum"},{"key":"10.1111\/j.1756-185X.2011.01643.x-BIB12|cit12","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1136\/ard.2004.031476","article-title":"Treatment continuation in patients receiving biological agents or conventional DMARD therapy","volume":"64","author":"Zink","year":"2005","journal-title":"Ann Rheum Dis"},{"key":"10.1111\/j.1756-185X.2011.01643.x-BIB13|cit13","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1111\/j.1479-8077.2005.00149.x","article-title":"Serum matrix metalloproteinase activity relating to cartilage destruction in rheumatoid arthritis","volume":"8","author":"Takemura","year":"2005","journal-title":"APLAR J Rheumatol"},{"key":"10.1111\/j.1756-185X.2011.01643.x-BIB14|cit14","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1111\/j.1756-185X.2009.01372.x","article-title":"Histological analysis of synovium by treatment of etanercept for rheumatoid arthritis","volume":"12","author":"Suzuki","year":"2009","journal-title":"Int J Rheum Dis"},{"key":"10.1111\/j.1756-185X.2011.01643.x-BIB15|cit15","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1002\/1529-0131(200011)43:11<2391::AID-ANR3>3.0.CO;2-F","article-title":"Systemic anti-tumor necrosis factor alpha therapy in rheumatoid arthritis down-regulates synovial tumor necrosis factor alpha synthesis","volume":"43","author":"Ulfgren","year":"2000","journal-title":"Arthritis Rheum"},{"key":"10.1111\/j.1756-185X.2011.01643.x-BIB16|cit16","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1007\/s10067-005-0129-6","article-title":"Efficacy of arthroscopic synovectomy for the effect attenuation cases of infliximab in rheumatoid arthritis","volume":"25","author":"Kanbe","year":"2006","journal-title":"Clin Rheumatol"},{"key":"10.1111\/j.1756-185X.2011.01643.x-BIB17|cit17","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1007\/s10067-008-0850-z","article-title":"Histological analysis of synovium in cases of effect attenuation associated with infliximab therapy in rheumatoid arthritis","volume":"27","author":"Kanbe","year":"2008","journal-title":"Clin Rheumatol"}],"container-title":["International Journal of Rheumatic Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1756-185X.2011.01643.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1111\/j.1756-185X.2011.01643.x\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,2,4]],"date-time":"2021-02-04T22:49:28Z","timestamp":1612478968000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1111\/j.1756-185X.2011.01643.x"}},"subtitle":["Histology of synovium treated by adalimumab"],"short-title":[],"issued":{"date-parts":[[2011,8]]},"references-count":17,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2011,8]]}},"URL":"https:\/\/doi.org\/10.1111\/j.1756-185x.2011.01643.x","relation":{},"ISSN":["1756-1841"],"issn-type":[{"value":"1756-1841","type":"print"}],"subject":[],"published":{"date-parts":[[2011,8]]}}}